Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Research

New cell and gene therapy manufacturing centre to help grow industry in UK

The Cell and Gene Therapy (CGT) Catapult, which aims to make the UK a world leader in development, delivery, and commercialisation of cell and gene therapy, has opened a new manufacturing centre to accelerate growth of the industry in the UK. The centre, which is based in Stevenage, Hertfordshire, was officially opened on 23 April 2018 by Greg Clark, business secretary, and Sam Gyimah, science minister.

The development of the new centre was backed by over £60m of UK government investment as part of its industrial strategy. It is hoped the centre will bridge the gap between scientific research and commercialisation of the medicines of the future.

The centre will provide the infrastructure for developing manufacturing capability and systems for large-scale cell and gene therapy clinical studies, and accelerate commercialisation.

It will also supply the network of Advanced Therapies Treatment Centres — joint ventures between universities, industry, and the NHS — which will specialise in the delivery of cell and gene therapy products. 

“By bringing together universities and businesses we can not only create the high-value jobs we need, but also develop potentially life-saving treatments,” said Gyimah.

“The UK is a world leader in science, research and innovation, and through our commitment to invest 2.4% of GDP [on research and development] by 2027, we are determined to seize the opportunities of tomorrow and help build a Britain fit for the future.”

Cell and gene therapies repair, replace, regenerate and re-engineer genes, cells and tissues to restore normal function or enhance their ability to fight diseases, such as cancer. By enabling collaborators to turn their cell and gene therapy innovations into commercially viable new medicines, the CGT Catapult will be supporting the routine delivery of these therapies to hospitals, clinics and patients, both in the UK and internationally.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204720

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Researcher pipetting drops of liquid into centrifuge flask

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.